Vascular Function of Breast Cancer Survivors on Aromatase Inhibitors Over Time by Nhan, Jessica
Poster Print Size:
This poster template is 36” high 
by 48” wide. It can be used to 
print any poster with a 3:4 aspect 
ratio.
Placeholders:
The various elements included in 
this poster are ones we often see 
in medical, research, and 
scientific posters. Feel free to 
edit, move,  add, and delete 
items, or change the layout to 
suit your needs. Always check 
with your conference organizer 
for specific requirements.
Image Quality:
You can place digital photos or 
logo art in your poster file by 
selecting the Insert, Picture 
command, or by using standard 
copy & paste. For best results, all 
graphic elements should be at 
least 150-200 pixels per inch in 
their final printed size. For 
instance, a 1600 x 1200 pixel 
photo will usually look fine up to 
8“-10” wide on your printed 
poster.
To preview the print quality of 
images, select a magnification of 
100% when previewing your 
poster. This will give you a good 
idea of what it will look like in 
print. If you are laying out a large 
poster and using half-scale 
dimensions, be sure to preview 
your graphics at 200% to see 
them at their final printed size.
Please note that graphics from 
websites (such as the logo on 
your hospital's or university's 
home page) will only be 72dpi 
and not suitable for printing.
[This sidebar area does not print.]
Change Color Theme:
This template is designed to use 
the built-in color themes in the 
newer versions of PowerPoint.
To change the color theme, 
select the Design tab, then 
select the Colors drop-down list.
The default color theme for this 
template is “Office”, so you can 
always return to that after trying 
some of the alternatives.
Printing Your Poster:
Once your poster file is ready, 
visit www.genigraphics.com to 
order a high-quality, affordable 
poster print. Every order 
receives a free design review 
and we can deliver as fast as 
next business day within the US 
and Canada. 
Genigraphics® has been 
producing output from 
PowerPoint® longer than anyone 
in the industry; dating back to 
when we helped Microsoft® 
design the PowerPoint® 
software. 
US and Canada:  
1-800-790-4001
Email: info@genigraphics.com
[This sidebar area does not print.]
Vascular Function of Breast Cancer Survivors on Aromatase 
Inhibitors Over Time
Jessica Nhan1; Josie van Londen, MD, MS2 ; Ashley Petersen, PhD1, 3; Anne H. Blaes, MD, MS1, 3; 
1University of Minnesota, 2University of Pittsburgh School of Medicine, 3University of Minnesota Masonic 
Cancer Center
INTRODUCTION
METHODS AND MATERIALS
CONCLUSIONS
DISCUSSIONRESULTS
REFERENCES
ABSTRACT
CONTACT
Graph 1. Changes in Estrone Levels 
Over Time
Graph 2. Changes in Estradiol Levels 
Over Time
Jessica Nhan
University of Minnesota- Twin Cities
Email: nhanx006@umn.edu
Background: Aromatase inhibitors (AIs) 
have been an effective method of 
reducing breast cancer mortality in 
estrogen receptor positive (ER+) breast 
cancer patients. However, AIs have been 
associated with risk factors of 
cardiovascular disease (CVD), such as 
hyperlipidemia and hypertension. The 
impact of AIs on body composition and 
overall cardiovascular risk continue to be 
unclear.
Methods: 18 postmenopausal women (9 
on AIs, 9 healthy controls) had physical 
measurements, blood samples, and 
DEXA scans of body fat composition 
collected at baseline, 4 weeks, 12 
weeks, and 52 weeks. 
Results: At baseline, the AI group had 
higher median weight (78.1 kg vs 63.9 
kg) and insulin level (10 units vs 5 units), 
suggesting that they may start at a 
higher risk for CVD than the controls. 
The median of changes from baseline to 
52 weeks of the AI group and control 
group were measured for total 
cholesterol (3 mg/dL vs 3.5 mg/dL, 
p=0.54), LDL (-10 mg/dL vs -2.5 mg/dL, 
p=0.92), HDL (1 mg/dL vs 8.5 mg/dL, 
p=0.31), blood pressure (systolic -3 
mmHg vs -10 mmHg, p=0.037; diastolic 
-1 mmHg vs -6.5 mmHg, p=0.47), lean 
body mass (0.46 kg vs 0.034 kg, 
p=0.37), total fat mass (-0.10 kg vs 0.27 
kg, p=1), and percent body fat (0.7% vs 
-0.3%, p=0.32).
Conclusion: These results suggest the 
use of AIs for ER+ breast cancer 
treatment may adversely increase the 
risk for CVD.
• At baseline, the AI group had higher median weight, initial 
insulin level, initial glucose level, BMI measurement, 
Insulin-like Growth Factor 1 (IGF-1) count, total cholesterol, 
low density lipoprotein (LDL) and very low density 
lipoprotein (VLDL) count, triglyceride count, testosterone 
levels, and total percent fat than the healthy control group
• At baseline, the AI group had a lower age, high density 
lipoprotein (HDL) count, estradiol levels, and globulin 
concentrations than the healthy control group
• In the changes in the physical data from baseline to 52 
weeks, the only variables with a p-value <0.05 were the 
VLDL count, triglyceride count, and estrone levels
• The variables above are also outlined in tables 1 & 2
• Higher median weight, BMI measurement, Insulin-like 
Growth Factor 1 (IGF-1) count, total cholesterol, 
triglyceride count, and total percent fat, all are 
contributing risk factors to CVD. At baseline, these 
variables were present at higher concentrations in the 
AI treatment group than in the healthy control, 
suggesting that the AI treatment group may already be 
at a higher risk for CVD prior to AI usage.
• Initial insulin levels were present at higher 
concentrations in the AI group than the control group. 
But one healthy control did not have data for that 
variable-- which could have skewed the data. 
However, initial glucose levels were also present at 
higher concentrations in the AI group than the control 
group, albeit not by much. High levels of glucose and 
insulin are precursors to diabetes, and diabetes 
increases risk for CVD.
• LDL and VLDL are considered to be the “bad” 
cholesterols, because high concentrations will 
increase CVD risk. At baseline, the AI group had 
higher concentrations of LDL and VLDL than the 
healthy control, suggesting that the AI group may 
already be at a higher risk for CVD prior to AI usage.
• Globulin binds to testosterone to degrade it, thus lower 
globulin concentrations indicates higher levels of free 
testosterone. Higher testosterone levels have been 
associated with a higher risk for CVD.
• The AI group overall were younger than the healthy 
controls. Despite being younger, the data suggests 
that they have a higher CV risk than the controls. 
These risks will continue to increase with age.
• The control group had higher HDL count and estradiol 
levels. HDL is the “good” cholesterol, associated with 
a lower CVD risk. Estradiol and estrone are derivatives 
of the hormone estrogen, which has also been 
associated with a lower CVD risk. 
• “Significant” data in table 2 (p-value <0.05) suggests 
that the contrast of risk for CVD between the AI group 
and control group increased during the study.
• One of the limitations of this study was the small 
sample size.
This study recruited 18 postmenopausal (55 to 85 years 
of age) women. Nine of the women were prescribed an 
AI treatment, and the other nine women were the 
healthy, age-matched controls. The inclusion criteria for 
the AI treatment group was women diagnosed with 
nonmetastatic, ER+ breast cancer, undergone 
lumpectomy (but not chemotherapy), and were currently 
prescribed to an AI. Exclusion criteria for both groups 
included tobacco users (defined as any tobacco use for 
the last three years), steroid users, or those diagnosed 
with a clinically significant thyroid abnormality. 
Participants in the study had physical measurements, 
blood samples, and DEXA body scans collected at 
baseline (before AI and radiation therapy), 4 weeks, 12 
weeks, and 52 weeks. IRB approval and informed 
consent was obtained. The data collected was analyzed 
using the Wilcoxon-Rank Sum test.
These results suggest the use of AIs for ER+ breast 
cancer treatment may increase triglyceride count, 
increase VDL count, and decrease estrone levels. 
Because of the associations mentioned in the discussion, 
these changes may adversely increase the risk for CVD.
Breast cancer is one of the most common cancer and 
leading causes of cancer death among women in the 
United States. It was estimated that in 2013, 
approximately 232,340 new cases of invasive breast 
cancer will be diagnosed and 39,620 deaths due to 
breast cancer will occur among US women. 
AIs have been an effective method of reducing breast 
cancer mortality in estrogen receptor positive (ER+) 
breast cancer patients. The AI works by blocking the 
activity of the aromatase enzyme, which is responsible 
for the synthesis of estrogen. The prevention of estrogen 
synthesis will thus inhibit tumor growth. 
However, there has been suggestions in literature 
about AI usage and related musculoskeletal pain, as well 
as risk factors of cardiovascular disease (i.e.: 
hyperlipidemia and hypertension). The association 
between AIs and risk factors for cardiovascular disease 
(CVD) need to be further explored. 
This poster presents the results of a prospective, 
observational pilot study on CV risk factors in females 
with breast cancer on AIs as compared to healthy 
controls.
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Table 1. Baseline Data in AI Group and Healthy Control Group
1 The summary shown is median (1st 
quantile, 3rd quantile)
2 One woman on AI is missing initial insulin 
measurements
Women on AIs1
(n = 9)
Healthy Controls1
(n = 9)
Baseline Age (years) 62 (60, 65) 67 (67, 74)
Weight (kg) 78.1 (73.9, 81.0) 63.9 (63.2, 70.9)
BMI (kg/m2) 29.8 (28.6, 31.9) 24.4 (22.8, 31.1)
Insulin-like Growth 
Factor 1 (ng/mL) 99 (72, 153) 94 (79, 138)
Total Cholesterol 
(mg/dL)
195 (189, 203)
188 (174, 202)
LDL (mg/dL) 127 (121, 137) 123 (96, 128)
VLDL (mg/dL) 21 (17, 30) 16 (15, 17)
HDL (mg/dL) 52 (42, 59) 62 (57, 69)
Triglycerides (mg/dL) 105 (84, 148) 82 (77, 83)
Estradiol (pg/mL) 48.4 (43.4, 58.4) 50.6 (33.5, 63.1)
Testosterone (ng/mL) 1.07 (0.477, 1.44) 0.406 (0.272, 0.824)
Globulin (nmol/L) 70.3 (45.7, 85.4) 97.7 (73.4, 126)
Initial Glucose (mmol/L) 94 (91, 96) 93 (91, 95)
Initial Insulin2 (units) 10 (4, 25) 5 (4, 7)
Total Fat (kg) 33.2 (28.4, 37.4) 19.5 (19.0, 28.4)
Total Lean (kg) 43.5 (40.4, 46.8) 42.0 (41.3, 44.8)
Total Percent Fat 40.3 (39.6, 44.3) 34.6 (29.4, 39.7)
1 The summary shown is median (1st 
quantile, 3rd quantile)
2 Two  women on AIs are missing IGF-1 
measurements at the week 52 visit
Women on AIs1
(n = 9)
Healthy Controls1
(n = 8)
p-value
Weight (kg) 1.2 (0.40, 2.2) 0.15 (-0.65, 0.57) 0.20
BMI (kg/m2) 0.53 (0.26, 0.84) 0.22 (-0.20, 0.38) 0.24
Insulin-like Growth 
Factor 12 (ng/mL) 10 (-1, 34) -16 (-28, 24) 0.32
Total Cholesterol 
(mg/dL) 3 (-4, 25) 3.5 (-12, 12) 0.54
LDL (mg/dL) -10 (-21, 8) -2.5 (-14, 3.8) 0.92
VLDL (mg/dL) 6 (3, 7) -3 (-6, 0.25) 0.010
HDL (mg/dL) 1 (-2, 10) 8.5 (0.75, 12) 0.31
Triglycerides (mg/dL) 30 (17, 33) -16 (-29, 1) 0.0045
Estrone (pg/mL) -10 (-19, -2.1) 3.3 (0.29, 6.6) 0.0093
Estradiol (pg/mL) -11 (-13, -9.9) -8.3 (-10, 0.98) 0.17
Testosterone (ng/mL) 0.048 (-0.083, 0.22) 0.036 (0.015, 0.18) 0.96
Globulin (nmol/L) -4.3 (-7.4, 2.3) 7.5 (-9.8, 14) 0.74
Total Fat (kg) 0.46 (0.043, 1.5) 0.034 (-1.0, 0.82) 0.37
Total Lean (kg) -0.10 (-1.5, 1.2) 0.27 (-0.34, 0.61) 1
Total Percent Fat 0.7 (-0.5, 1.9) -0.3 (-1.7, 0.8) 0.32
Table 2. Changes in Data from Baseline to Week 52 in AI Group and Healthy Control Group
